---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-207466"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2024-08-27T23:59:59+00:00"
generated_at: "2026-05-31T07:27:13.019391+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Invivyd's pemivibart shows 84% relative risk reduction in symptomatic COVID-19 in Phase 3 exploratory analysis

## Summary
- 84% relative risk reduction vs placebo (1.9% vs 11.9% symptomatic COVID-19 rate, p=0.000061) over 180 days in immunocompetent cohort.
- Immunocompromised cohort: 3% symptomatic COVID-19 rate; no COVID-19 hospitalizations or deaths over 180 days.
- Safety: anaphylaxis in 0.6% of immunocompromised cohort (2 life-threatening); infusion reactions generally mild-moderate.
- FDA updated PEMGARDA Fact Sheet for Healthcare Providers to include 180-day exploratory efficacy data.
- Data collected during XBB/JN.1 variant waves; company to host conference call at 8:30AM EDT today.

## SEC filing metadata
- accession: 0001193125-24-207466
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2024-08-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000119312524207466/0001193125-24-207466-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000119312524207466/d890200d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-207466
- JSON: https://secwatch.observer/filing/0001193125-24-207466.json
- Plain text: https://secwatch.observer/filing/0001193125-24-207466.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.